AB SCIEX QTRAP 5500 System

AB SCIEX QTRAP 5500 系统

• 批准号: 7793764
• 负责人: Sharyn D Baker
• 金额: $ 40.5万
• 依托单位: ST. JUDE CHILDREN'S RESEARCH HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-04-22 至 2011-04-21
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7793764
• 关键词: Acute Lymphocytic Leukemia; Antineoplastic Agents; Arts; Biological; Biological Assay; Chemicals; Child; Development; Disease; Drug Kinetics; Ependymoma; Equipment; Funding; Glioma; Innovative Therapy; Lead; Malignant Childhood Neoplasm; Malignant Neoplasms; Mass Spectrum Analysis; Mission; Modality; Modeling; Molecular Genetics; Peer Review; Pharmacodynamics; Pre-Clinical Model; Research; Research Personnel; Retinoblastoma; Saint Jude Children' s Research Hospital; Sampling; Solid Neoplasm; Specificity; System; Therapeutic; Translational Research; Translations; analytical method; base; drug discovery; indexing; innovation; insight; medulloblastoma; novel; pre-clinical; programs; public health relevance; small molecule

DESCRIPTION (provided by applicant): The primary mission of St. Jude Children's Research Hospital is to find cures for children with cancer and other catastrophic diseases through research and treatment. Recent progress at St. Jude has provided a better understanding of the molecular, genetic and chemical bases of cancer in children. These findings have provided new insights into novel targets and treatment modalities for multiple cancers. An extensive therapeutic drug discovery program at St. Jude has identified lead compounds to evaluate in novel preclincial models of childhood cancer. The long-term objective of this application is to support the preclinical development of novel small molecules and their translation to innovative strategies for childhood cancers including acute lymphoblastic leukemia, ependymoma, medulloblastoma, glioma, retinoblastoma and other solid tumors. With the proposed state-of-the-art LC/MS/MS system, the specific aim is to develop, validate and implement sensitive and specific analytical methods for anticancer agents, their metabolites, or other relevant pharmacologic indices in biological samples to facilitate high-quality pharmacokinetic/ pharmacodynamic translational research in pre-clinical models at St. Jude. The proposed equipment will benefit five competitively funded peer-reviewed investigators and their projects through greater assay selectivity, specificity, efficiency, and consistency in application of state-of-the-art equipment and approaches to preclinical pharmacokinetic projects. PUBLIC HEALTH RELEVANCE: Recent progress at St. Jude has provided a better understanding of the molecular, genetic and chemical bases of cancer in children. This project will provide state-of-the-art analytical methods based on mass spectrometry to support the preclinical development of novel small molecules and their translation to innovative therapies for children with cancer.

描述（由申请人提供）：圣裘德儿童研究医院的主要任务是通过研究和治疗为患有癌症和其他灾难性疾病的儿童找到治疗方法。圣裘德的最新进展为儿童癌症的分子，遗传和化学碱提供了更好的了解。这些发现为多种癌症的新目标和治疗方式提供了新的见解。圣裘德（St. Jude）的广泛治疗药物发现计划已经确定了铅化合物，以评估新型儿童癌症模型。该应用的长期目的是支持新型小分子的临床前发展，并将其转化为儿童期癌症创新策略，包括急性淋巴细胞白血病，沉积物瘤，髓母细胞瘤，胶质瘤，视网膜细胞瘤，视网膜细胞瘤和其他实体瘤。借助拟议的最先进的LC/MS/MS系统，具体的目的是为抗癌剂，其代谢物或其他相关的药理学指数开发，验证和实施敏感和特定的分析方法，以促进St. Jude的高素质药物动力学/药物动力学研究。拟议的设备将通过更大的选择性，特异性，效率和一致性在适用于临床前药代动力学项目的最先进设备和方法中，使五个竞争性资助的经过同行评审的研究人员及其项目受益。 公共卫生相关性：圣裘德的最新进展为儿童癌症的分子，遗传和化学基础提供了更好的了解。该项目将基于质谱法提供最新的分析方法，以支持新型小分子的临床前发展及其转化为癌症儿童的创新疗法。